Leukemia
VIDEO: IDH inhibitor treatment sequence for AML a 'hot topic of discussion' at ASH
In this video, Akriti Jain, MD, discusses whether patients with acute myeloid leukemia with IDH mutations should be treated with IDH inhibitors up front compared to venetoclaxcontaining regimens.
Revumenib represents a ‘significant breakthrough’ for treatment of acute leukemia
Revumenib proved safe and effective among pediatric and adult patients with relapsed or refractory KMT2Ar acute myeloid leukemia and acute lymphoid leukemia, according to study results presented at ASH Annual Meeting and Exhibition.
‘Multi-pronged approach’ needed to increase diversity in clinical trials
In a special scientific session on race and science at ASH Annual Meeting an Exposition, Saad Z. Usmani, MD, MBA, FACP, FRCP, examined clinical trial inclusion from an investigator’s perspective.
Study yields 'encouraging' preliminary data for navitoclax combination in myelofibrosis
SAN DIEGO — Navitoclax added to ruxolitinib led to a significant improvement in spleen volume reduction compared with placebo among patients with untreated myelofibrosis, study results presented at ASH Annual Meeting and Exposition showed.
Study suggests ‘significant’ link between sickle cell trait, leukemia
SAN DIEGO — Individuals with sickle cell trait are at increased risk for leukemia, specifically myeloid and monocytic leukemias, according to data presented at ASH Annual Meeting and Exposition.
Oral regimen provides curative, chemotherapy-free treatment of acute promyelocytic leukemia
SAN DIEGO — Oral arsenic trioxide proved safe and effective when used as part of a regimen for treatment of acute promyelocytic leukemia, study results presented at ASH Annual Meeting and Exhibition showed.
AI tool addresses ‘clinical conundrum’ by accurately identifying rare blood cancers
SAN DIEGO — An international group of researchers developed an artificial intelligence-based algorithm that differentiates prefibrotic primary myelofibrosis from essential thrombocythemia during pathological analysis, study findings showed.
Using pharmacogenomics to guide induction may reduce racial disparities in pediatric AML
Outcomes among children with acute myeloid leukemia treated with high-dose cytarabine-based regimens did not vary by race, according to study results presented at ASH Annual Meeting and Exposition.
FDA approves Jaypirca for chronic lymphocytic leukemia, small lymphocytic lymphoma
The FDA granted accelerated approval to pirtobrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Q&A: Supportive care in young adults with leukemia
Healio spoke with Nikki Yuill, LCSW, and Michelle Rajotte, LMSW, the director and associate director of The Leukemia & Lymphoma Society’s Information Resource Center, about the importance of supportive care in young adults with leukemia.